Phreesia, Inc. · NYSE:PHR

Phreesia — Investor Presentation (December 2020)

19 slides from Phreesia's investor presentation, December 2020

  1. Slide 1: Investor Presentation December 2020

    Investor Presentation December 2020

  2. Slide 2: Disclaimers and Forward-Looking Statements

    DISCLAIMERS AND FORWARD-LOOKING STATEMENTS Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking st

  3. Slide 3: Our Mission

    OUR MISSION To create a better, more engaging healthcare experience 3

  4. Slide 4: Phreesia is Patient Intake

    ~1,600 healthcare is Patient Intake provider organizations ~$1.9B patient payments processed in FY20 Who we are: Leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care $125M revenue in FY20 What we do: Enable healthcare provider organi

  5. Slide 5: Attractive Industry Tailwinds

    ATTRACTIVE INDUSTRY TAILWINDS Wasteful Increasing Patient Increasing Shift to Value-Based Focus on Spending Responsibility Consumerism Care Models Personalized Healthcare Solutions • 1.2M intake staff • $586B out-of- • Demand for higher • Payment model • Need to directly represent $37B in pocket spe

  6. Slide 6: Our Value Proposition and How We Make Money

    OUR VALUE PROPOSITION AND HOW WE MAKE MONEY Providers Patients Life Sciences Companies • Simplified operations & enhanced • Improved patient experience • Targeted, direct digital marketing Value proposition staff efficiency • High patient usage • Improved brand conversion and • Improved cash flow an

  7. Slide 7: Our End-to-End Patient Intake Solution

    OUR END-TO-END PATIENT INTAKE SOLUTION Patients Use These: Staff Use These: AT HOME, ON THE GO, IN THE OFFICE IN THE OFFICE IN THE OFFICE IN THE OFFICE PhreesiaPad Mobile Arrivals Station Phreesia Dashboard Analytics Real-time Integration Electronic Practice Telehealth Practice Data Payment Medical

  8. Slide 8: The Phreesia Platform

    THE PHREESIA PLATFORM Registration Revenue Cycle Appointments Patient Activation Clinical Support Life Sciences Online appointment Branded patient COVID-19 Screening Intake Workflows Insurance verification Patient Connect requests announcements Module Clinical screening tools Appointments queue Cons

  9. Slide 9: Our Current Addressable Market

    OUR CURRENT ADDRESSABLE MARKET Consumer-Related Transaction Subscription-Based Revenue Life Sciences And Payment Processing Fees ~50K addressable provider clients1 $93B addressable out-of-pocket3 DTC point-of-care in United States in United States marketing spend4 ~1.3M individual providers2: ~1.0M

  10. Slide 10: Scalable from Small Businesses to Large Enterprises

    SCALABLE FROM SMALL BUSINESSES TO LARGE ENTERPRISES 25+ medical specialties of varying sizes ~40 life sciences brands Providers Life Sciences Physician groups Health systems Pharma manufacturers • Top 3 global pharma company • Top 3 global biotech company z • Top 5 diabetes pharma manufacturer • Top

  11. Slide 11: Phreesia Is the 2020 Best in KLAS Patient Intake Management Solution

    Phreesia Is the 2020 Best in KLAS Patient Intake Management Solution In its annual “Best in KLAS: Software and Services” report, KLAS named Phreesia the 2020 Best in KLAS for Patient intake Management, based on survey data from provider groups on areas such as integration, implementation support and

  12. Slide 12: Multiple Growth Opportunities

    MULTIPLE GROWTH OPPORTUNITIES Grow footprint Cross-sell new Margin Partnerships and Land new clients within existing applications to expansion M&A clients existing clients through scale • Direct sales model • Additional providers • Proven ability to • New applications • Opportunistic • Acute care ma

  13. Slide 13: Financial Overview

    Financial Overview 13

  14. Slide 14: Strong Operating and Financial Profile

    STRONG OPERATING AND FINANCIAL PROFILE • Strong visibility into revenue at the beginning of the fiscal period based on contracted business • 80%+ revenue from recurring monthly subscriptions and re-occurring payment processing fees Highly Visible • Contracts typically 1-year in length Revenue • Stro

  15. Slide 15: Scalable and Predictable Sources of Revenue

    SCALABLE AND PREDICTABLE SOURCES OF REVENUE REVENUE MODEL DRIVERS FY20 % REV Subscription and related • New provider clients services1 • Includes base package and add-on applications • Majority of fees charged per provider per month (PPPM) • Expansion within existing clients 45% • New products and a

  16. Slide 16: Strong Operating and Financial Performance

    STRONG OPERATING AND FINANCIAL PERFORMANCE AVG. NUMBER OF AVG. PROVIDER TOTAL REVENUE ($M) PROVIDER CLIENTS REVENUE PER CLIENT ($K) ADJ. EBITDA ($M)1 Life Sciences Provider +25% +21% +10% $125 1,737 $65,486 $100 +5% +27% $54,231 +17% 1,571 1,573 $10 +5% 3 $38 1,490 $33 $17,490 $81 $16,637 +16% $30 $

  17. Slide 17: Appendix

    Appendix 17

  18. Slide 18: Detailed Income Statement

    DETAILED INCOME STATEMENT $M Fiscal year ended January 31 Three months ended October FY 2019 FY 2020 Q3 2020 Q3 2021 Revenue: Subscription and Related Services Revenue $43.9 $56.4 $14.6 $17.5 Payment Processing Revenue 36.9 46.5 11.6 12.9 Total Provider Revenue $80.8 $102.9 $26.2 $30.4 Life Sciences

  19. Slide 19: Adjusted EBITDA Reconciliation

    ADJUSTED EBITDA RECONCILIATION1 $M Fiscal year ended January 31, Three months ended October FY 2019 FY 2020 Q3 2020 Q3 2021 Reconciliation to Adjusted EBITDA Net Income (Loss) ($15.1) ($20.3) ($2.4) ($6.7) Interest (Income) Expense 3.5 2.4 0.2 0.5 Depreciation and Amortization 11.6 13.9 3.5 4.0 Stoc

Phreesia — Investor Presentation (December 2020) on 6ix